Coverage
-
August 23, 2023
The Ninth Circuit on Wednesday agreed to review a grant of class certification in a suit by third-party payors alleging that Takeda Pharmaceutical Co. and Eli Lilly & Co. hid risks associated with their anti-diabetes drug Actos.
1 other articles on this case.
View all »